Compare SAH & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SAH | NRIX |
|---|---|---|
| Founded | 1997 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.6B |
| IPO Year | 1997 | 2020 |
| Metric | SAH | NRIX |
|---|---|---|
| Price | $61.54 | $25.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 14 |
| Target Price | ★ $88.91 | $34.50 |
| AVG Volume (30 Days) | 271.3K | ★ 1.9M |
| Earning Date | 10-29-2026 | 10-12-2026 |
| Dividend Yield | ★ 2.60% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.58 | 3.26 |
| Revenue | ★ $9,951,630,000.00 | $76,987,000.00 |
| Revenue This Year | $3.60 | $786.93 |
| Revenue Next Year | $4.33 | N/A |
| P/E Ratio | $17.67 | ★ $7.82 |
| Revenue Growth | 0.86 | ★ 99.31 |
| 52 Week Low | $54.11 | $11.19 |
| 52 Week High | $113.67 | $28.23 |
| Indicator | SAH | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 42.51 | 58.20 |
| Support Level | $59.30 | $24.61 |
| Resistance Level | $65.77 | $28.23 |
| Average True Range (ATR) | 2.56 | 1.21 |
| MACD | 0.71 | 0.39 |
| Stochastic Oscillator | 30.07 | 81.41 |
Sonic Automotive is one of the largest auto dealership groups in the United States. The company has 107 franchised stores in 18 states, primarily in metropolitan areas in California, Texas, and the Southeast, plus 18 EchoPark used-vehicle stores in 10 states, 16 collision centers, and 20 powersports locations. The franchise stores derive revenue from new and used vehicles plus parts and collision repair, finance, insurance, and wholesale auctions. Luxury and import dealerships make up about 86% of franchise new-vehicle revenue, while Honda, BMW, Mercedes, and Toyota constitute about 56% of new-vehicle revenue. BMW is the largest brand at about 23%. 2025 revenue was $15.2 billion, with Texas and California constituting 51% of the total. EchoPark's portion was $2.1 billion.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.